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ABSTRACT
Besides somatic mutations or drug efflux, epigenetic reprogramming can lead 
to acquired drug resistance. We recently have identified early stress-induced multi-
drug tolerant cancer cells termed induced drug-tolerant cells (IDTCs). Here, IDTCs 
were generated using different types of cancer cell lines; melanoma, lung, breast and 
colon cancer. A common loss of the H3K4me3 and H3K27me3 and gain of H3K9me3 
mark was observed as a significant response to drug exposure or nutrient starvation 
in IDTCs. These epigenetic changes were reversible upon drug holidays. Microarray, 
qRT-PCR and protein expression data confirmed the up-regulation of histone 
methyltransferases (SETDB1 and SETDB2) which contribute to the accumulation of 
H3K9me3 concomitantly in the different cancer types. Genome-wide studies suggest 
that transcriptional repression of genes is due to concordant loss of H3K4me3 and 
regional increment of H3K9me3. Conversely, genome-wide CpG site-specific DNA 
methylation showed no common changes at the IDTC state. This suggests that 
distinct histone methylation patterns rather than DNA methylation are driving the 
transition from parental to IDTCs. In addition, silencing of SETDB1/2 reversed multi 
drug tolerance. Alterations of histone marks in early multi-drug tolerance with an 
increment in H3K9me3 and loss of H3K4me3/H3K27me3 is neither exclusive for any 
particular stress response nor cancer type specific but rather a generic response.
INTRODUCTION
Tumours that are initially sensitive to a particular 
drug often develop resistance through a range of 
different mechanisms including somatic mutations, drug 
efflux, increased expression of the therapeutic target, 
DNA damage repair, cell death inhibition, activation of 
alternative signalling pathways, or epithelial-mesenchymal 
transition (EMT) [1-3]. Recent evidence indicates 
that drug resistance is often established without stable 
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resistance-conferring genetic alterations [4, 5]. This entails 
alternative mechanisms such as epigenetic reprogramming 
for developing acquired resistance [6, 7]. Several studies 
have shown that cancer patients, who initially respond 
well to chemo- or molecularly targeted therapy but acquire 
resistance, can become re-sensitized to these same drugs 
by providing a “drug holiday”, a period without drug 
treatment [8, 9]. This is called ‘retreatment response’ [10, 
11] and suggests that in some cases acquired resistance is 
a reversible effect. Moreover, we have previously found 
that transient but still reversible acquired drug resistance 
develops as a generic stress response rather than selection 
for a particular subpopulation demonstrating phenotypic 
plasticity contributing to drug resistance [12]. The 
underlying mechanisms and their relative contribution 
to cancers are still elusive. Initial studies on epigenetic 
modifications in cancer relied heavily on global DNA 
hypo-methylation [13] and later hyper-methylation at the 
promoter CpG island region of tumour suppressor genes 
[14]. Later on, histone modifications have been identified 
as one of the key epigenetic modifications in cancer [15]. 
Epigenetic modifications are not independent events 
rather they act in conjunction with chromatin modifiers 
like histone deacetylase (HDACs) and histone methyl-
transferase (HMTs) maintaining particular histone marks 
[16]. These key epigenomic regulators are frequently 
dysregulated in different cancer types [17].
Based on our recent findings in melanoma [12], 
histone modifications and DNA methylation were 
studied in early stress-induced drug-tolerant cancer cells 
(IDTCs) from different cancer types. Our data suggest 
that IDTCs undergo an analogous inherent transcriptional 
reprogramming defined by a significant genome-wide 
downregulation of gene expression. Independent of the 
global DNA methylation remodelling, this response was 
defined by a significantly increased level of H3K9me3, 
a repressive histone modification at gene-associated 
polycomb repressive domains (PRDs) and decreased level 
of H3K4me3, an activating histone modification at gene 
promoters and H3K27me3, a transcriptional enhancer-
repressive modification, irrespective of the treatment 
regime and cellular origin.
RESULTS
Transition from parental to induced drug-tolerant 
cells is a generic feature of cancer cells
We previously demonstrated that BRAF mutant 
(mt) melanoma cells exposed to sub-lethal concentrations 
of a drug, hypoxia or nutrient starvation for 12 to 15 
days convert into multi-drug tolerant cells [12]. These 
are termed induced drug-tolerant cells (IDTCs). To 
determine whether this innate response is cancer type 
specific, we generated IDTCs from NRAS mt melanoma 
(WM1366), KRAS mt lung (A549), PIK3CA mt breast 
(SKBR3), and KRAS mt colon (HT29) cancer cell lines 
by exposing them to sub-lethal concentrations of either 
chemotherapy or specific targeted therapies. WM1366 and 
SKBR3 IDTCs were generated using 5nM of docetaxel, 
A549 IDTCs with500nM of doxorubicin, and HT29 
IDTCs using 25nM dabrafenib and 10nM of trametinib 
(Supplementary Table 1). Cell growth was determined 
after 12 days of drug exposure. Parental cells survived at 
lower sub-lethal concentrations such as 5nM docetaxel 
(WM1366 and SKBR3), 500nM or 1μM  of doxorubicin 
(A549), and a combination of 25nM dabrafenib and 10nM 
trametinib (HT29) (Figure 1a and Supplementary Figure 
1a). To assess the multi-drug resistance potential, IDTCs 
generated at 500nM doxorubicin and 5nM docetaxel 
were then exposed to a substantially higher dosage of the 
same drugs (2.5µM doxorubicin and 30nM docetaxel) in 
addition to 5µM of sorafenib and 80nM of cisplatin. In 
agreement with our previous observations [12], IDTCs 
generated from A549, WM1366, and SKBR3 survived 
at the higher dosage compared to their respective 
parental cells, demonstrating the development of multi-
drug tolerance promoted by continued exposure to low 
drug concentrations (Figure 1b). As we have observed 
previously in melanoma, all IDTC lines developed 
from the four different cancer cell lines showed altered 
morphology compared to their parental cells. IDTCs had 
a more flattened, elongated and translucent phenotype 
compared to parental cells (Figure 1c and Supplementary 
Figure 1b). We have also demonstrated that CD271 is a 
characteristic marker of IDTCs in a BRAF mt melanoma 
model [12]. Concordantly, we observed that IDTCs from 
all four cancer cell lines showed a significant increase in 
CD271 expression (Figure 1d and Supplementary Figure 
1c-d). Additionally, all IDTCs had increased activation 
of MAPK, AKT, and mTOR pathways, as previously 
demonstrated for the BRAF mt melanoma IDTCs [12]
(Figure 1e). Other cellular stressors, such as low glucose 
media, also produced IDTCs with comparable signalling 
pathway activation (Figure 1f). These results were further 
corroborated by reverse phase protein array (RPPA) 
analyses of WM1366, A549, and HT29 IDTCs and their 
respective parental cells. RPPA results showed increased 
activation of JAK-STAT, AKT, and MEK signalling across 
the different cancer types suggesting a survival advantage 
of IDTCs over parental cancer cells (Supplementary 
Figure 1e).
A distinct histone methylation pattern defines 
IDTCs
We previously compared differences in gene 
expression between parental and BRAF mt melanoma 
IDTCs (WM164) and identified significant changes 
in epigenetic factors leading to an altered chromatin 
Oncotarget8208www.impactjournals.com/oncotarget
Figure 1: A common stress-induced transition of cancer cells into induced drug-tolerant cells (IDTCs). a. WM1366, 
SKBR3 or A549 cells were exposed to either dimethyl sulphoxide (DMSO), docetaxel (DC; 5nM, 10nM, 20nM; WM1366, SKBR3) 
or doxorubicin (Dx; 500nM, 1µM and 2.5µM; A549) for a period of 12 to15 days. Experiments were performed in biological triplicate. 
Surviving cells were stained with crystal violet (well images), then dissolved in 10% acetic acid and measured at 570nm to provide the 
relative cell number of viable cells. Crystal violet staining at day one after seeding was used as loading control compared with 12-15 days’ 
time point. Error bars represent the standard deviation from the mean. b. In a separate experiment, 5nM docetaxel and 500nM doxorubicin 
IDTCs were further exposed to higher concentrations of doxorubicin at 2.5µM, docetaxel at 30nM, cisplatin at 80µM and sorafenib at 
5µM in biological triplicate. Relative survival of IDTCs compared to parental cells was measured by crystal violet staining after 72hrs. 
Statistical analysis was performed by unpaired t-test and P-value is represented as (*) where, ****P < 0.0001, ***P < 0.001, **P < 0.01, 
and *P < 0.05. c. Morphological changes during the transition of parental cells to IDTCs in WM164 and A549 cells (10x magnification). d. 
Expression of CD271 in WM1366 and A549 IDTCs compared to untreated control by IF. Representative CD271 (red) and Hoechst staining 
(blue) overlay images are shown. IgG isotype control is shown in Supplementary Figure 1e. (10x Magnification and bar is 100µm long) e. 
Protein lysates from IDTCs and the untreated control were subjected to immunoblotting for expression levels of the indicated antibodies. f. 
Indicated cell lines were maintained in low glucose (1mg/ml) containing media for 12-15 days. Cell lysates from low glucose IDTCs and 
normal glucose controls were probed for the indicated proteins. All western blot images were quantified by ImageJ software. Values were 
normalized by subtracting from loading control.
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state [12]. Three histone demethylases involved in the 
removal of the active transcription mark H3K4me3 
(KDM5A, KDM5B) and repressive mark H3K27me3 
(KDM6A), as well as one histone methyltransferase 
(SETDB1) responsible for the establishment of the 
repressive H3K9me3 mark, were upregulated in IDTCs 
(Supplementary Figure 2a). To determine whether this 
is a common feature associated with the acquisition 
of drug tolerance, we evaluated these histone marks 
in IDTCs generated from different cancer types. We 
observed a consistent increase of H3K9me3 and decrease 
of H3K4me3 and H3K27me3 in IDTCs (Figure 2a and 
Supplementary Figure 2b-2c). Immunofluorescence (IF) 
quantification confirmed that H3K9me3, H3K4me3, and 
H3K27me3 showed significant differences (P < 0.0001) 
between parental cells and IDTCs (Supplementary Figure 
2c). Stress due to nutrient starvation mimicked the histone 
modification patterns (P < 0.0001) suggestive of a generic 
stress response in cancer (Figure 2b). Additionally, two 
histone modifications H3S28ph and H4K16ac were tested 
which has been reported to be involved in acute cellular 
stress [18] and frequently lost in cancer respectively [19]. 
No significant differences were observed between IDTCs 
and parental cells (Supplementary Figure 2d and 2e).
Drug holidays reverse histone alterations involved 
in the IDTC state
It has been demonstrated that a phenotypic switch 
as a result of drug holidays restores sensitivity to both 
chemotherapy and targeted therapy [11, 20]. We have 
demonstrated that drug sensitivity of IDTCs is restored 
by allowing drug holidays in melanoma cell IDTCs [12]. 
Importantly, drug holidays dynamically modulate histone 
modifications with an increase of the H3K4me3 and 
H3K27me3 mark and a decrease of the H3K9me3 mark 
akin the parental histone modification landscape in all cell 
types assessed (Figure 2c). This also corresponded to a 
phenotypic switch leading to re-sensitization to the drug 
they were originally desensitised to (Figure 2d).
Common gene expression variations in IDTCs
To identify differentially expressed genes in 
IDTCs, parental and IDTCs (WM1366, A549, HT29, and 
HCC827) were analysed for genome-wide expression 
by microarrays. Overall, there was a significant (P < 
0.05) global down-regulation of gene expression in 
response to different drugs regardless of targeted or 
chemotherapy (Figure 3a, 3b and Supplementary Figure 
3a). We identified cell type-specific and common gene 
expression variations affecting biological processes, 
cellular location, and molecular functions in IDTCs 
(Supplementary Figure 3b). Pathway enrichment analyses 
showed that genes involved in IFN-α, -β, -γ  signalling, 
and cytokine signalling are altered in IDTCs (Figure 
3c, Supplementary Figure 4). Enriched pathways were 
analysed for overall upregulated genes in IDTCs and 
perceived as a response to type 1 IFN (GO: 0034340), 
type 1 interferon signalling pathway (GO:0060337), 
cellular response to type 1 IFN (GO:0071357), and innate 
immune response (GO:0045087) (Supplementary Figure 
5 and Supplementary Figure 6). This suggested that in 
response to targeted therapy and chemotherapy, cancer 
cells survive at an early state of stress-induced drug 
tolerance by increasing interferon signalling maintaining 
a slow proliferative state.
Paucity of changes in global DNA methylation 
characterizes IDTCs
We then investigated DNA methylation as one 
of the plausible mechanisms of the repressive state in 
IDTCs. DNA methylation is reported to drive acquired 
drug resistance [21] and to interact with repressive 
histone marks like H3K9me3 in different cancer types 
[22]. In addition, we detected differential expression of 
three DNA methyltransferases DNMT3A, DNMT3B, and 
DNMT1 in IDTCs compared to parental cells, suggesting 
potential re-distributions of DNA methylation patterns 
in IDTCs (Supplementary Figure 7a). Genome-wide 
DNA methylation analyses were performed in biological 
triplicates using the HM450K BeadChip in four IDTC 
models (WM1366, WM164, A549, and HT29). Parental 
DNA methylation patterns were significantly different 
among the four cancer types ranging from a high global 
DNA methylation level in HT29 (mean β value = 0.62) to 
a low global DNA methylation level in WM164 (mean β 
value = 0.49; Supplementary Figure 7b). Particularly, we 
observed that global DNA methylation changes in each 
cell type followed different trends independent of the 
initial DNA methylation level. Thus, while IDTC HT29 
showed substantial global hypo-methylation, IDTCs A549 
and WM1366 presented moderate hyper-methylation and 
IDTC WM164 a substantial global hyper-methylation 
(Figure 3d).We then analysed the genomic context of 
the differentially methylated CpG sites for all pairs and 
found that, independently of the cancer type, the most 
significantly affected genomic regions were low CpG 
density segments named “Open Sea” (Supplementary 
Figure 7c). Mainly due to the substantial differences in 
intrinsic DNA methylation patterns among the four cell 
lines no common significantly differentially methylated 
CpG sites were found (adjusted p-value < 0.05) when 
comparing parental to IDTCs (Figure 3e). However, 
when comparing methylation profiles of IDTCs and 
their respective parental cells, we found significant 
differentially methylated regions (adjusted p-value < 0.05) 
suggesting that DNA methylation re-distribution in IDTCs 
is not a generalized mechanism, but a cell-type specific 
response to sustained drug exposure (Figure 3f).
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Figure 2: Stress and drug holidays dynamically modulate histone modifications. a. WM1366, A549 IDTCs and their parental 
cells were tested for H3K4me3, H3K9me3 and H3K27me3 antibodies by IF. Representative antibodies staining and Hoechst (nuclear) 
staining were taken separately and overlaid picture are shown. b. A549 and SKBR3 cells were cultured with 1mg/ml glucose containing 
media for at least 12 days. Media was replenished after every three days. IF was performed for the indicated Abs to compare to parent cells 
supplemented with 5mg/ml glucose media. c. WM1366, SKBR3 and A549 IDTCs were allowed a drug holiday for ten days. During this 
period of time, no drug was provided and media changed every 72 hrs. Histone modifications were analysed by IF with the indicated Abs 
compared to corresponding parental cells. (All of the IF image were taken at 10x Magnification and bar is 100µm long) d. After 10 days 
of drug holidays WM1366, A549 and HT29 IDTCs were exposed to toxic concentrations of doxorubicin (2.5µM), docetaxel (30nM) for 
WM1366, A549 and dabrafenib (500nM) and docetaxel (30nM) for HT29. Cell survival was analysed by MTT assay. All experiments were 
done in triplicate. Statistical analysis was performed by the one-way ANOVA test and P-value is represented as (*) where, ****P < 0.0001.
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Figure 3: Differential expression of genes and genome wide DNA methylation in IDTCs compared to parental cells. a. 
Hierarchical clustering of differential gene expression. Four cancer cell lines were analysed by the Australian Genome Research Facility 
(AGRF) for genome-wide differential expression using Illumina expression arrays. An unbiased hierarchical clustering was developed 
using the Mann-Whitney unpaired test with a fold change cut off FC≥ 1.5 and P≤0.05 as shown in the figure. b. A volcano plot was 
generated with a similar threshold as mentioned above depicting the overall 293 up and down-regulated genes. c. Pathways enriched for 
each of the IDTCs compared to parent cells are shown by using cluster Profiler7, with a p-value and a q-value cut off of 0.1 and 0.05 
respectively. Genome-wide DNA methylation analyses reveal cell type-specific changes at the IDTC state. d. DNA methylation levels of 
IDTCs compared to untreated control. Bars represent the mean DNA methylation level for each cell line, with (IDTC) and without (CTRL) 
treatment. Error bars = S.E.M. e. Venn’s diagrams representing commonly differentially methylated (hypo- or hyper-methylated) CpG sites 
in IDTCs compared to control. f. Hierarchical clustering for cell-type using differentially methylated CpG sites. Differentially methylated 
CpG sites between the groups were identified using the Rank Products test [54]. After 100 permutations, CpG sites showing an adjusted 
p-value<0.05 (q-value) were considered significant. Scale bar for beta values: Green = 0 Black = 0.5 and Red = 1.
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Genome-wide redistribution of histone marks 
defines IDTCs
The characteristic changes of histone marks in 
IDTCs prompted us to further investigate the whole-
genome distribution of H3K4me3, H3K27me3 and 
H3K9me3 modifications in WM164 IDTCs compared 
to untreated control by ChIP-seq. Overall, an increased 
level of H3K9me3 decreased level of H3K4me3 and 
relatively unchanged level of H3K27me3 was observed 
in IDTCs (Figure 4a, upper panel). To evaluate the 
influence of histone modifications on gene expression 
regulation, we evaluated changes in the genomic 
vicinity of IDTC down-regulated genes (fold change -2; 
n = 1,423). In concordance with repressive epigenomic 
reprogramming, a characteristic peak distribution of 
H3K4me3 on transcriptionally active genes was observed 
in paternal cells which decreased around the distal 
(±1.5kb) transcription start sites (TSSs) in IDTC cells. 
Additionally, the level of H3K9me3 was increased in 
distal promoter region (>5kb away from the TSSs) and 
proximal regulatory elements of negatively-regulated 
genes in IDTCs (Figure 4a, lower panel). Moreover, we 
identified that 1,245 of the 1,461 down-regulated genes 
were associated with polycomb repressive domains 
(PRDs). Interestingly, we observed a gain of H3K9me3 
levels in these regions which might be associated with 
transcriptional repression of these genes (Figure 4b). 
Overall, we observed significant overlapping between 
down-regulated genes and gain on H3K9me3 (n = 487; 
P = 5.38x 10-22), between up-regulated genes and gain on 
H3K4me3 histone marks (n = 138; P = 3.15x10-12) and 
down-regulated genes with repressive H3K27me3 mark 
(n = 370. P = 0.03, Figure 4c). To further understand the 
genomic context of the regions exhibiting changes on 
histone modifications in drug tolerance, we integrated 
our data with the core 15 states chromatin maps 
generated from 127 human epigenomes [23]. Genomic 
regions with concomitant gains in H3K9me3 and loss 
of H3K4me3 defined domains of low transcriptional 
activity significantly overlapped with PRDs (Figure 4d). 
This suggests that concordant modulation of active and 
repressive histone marks may lead to transcriptional 
activation or repression in IDTCs.
Increased H3K9me3 is characterized by dynamic 
expression of histone modifiers
The increase in H3K9me3 prompted us to test 
for different known histone modifiers. H3K9me3 is 
catalysed by a set of specific histone methyltransferases 
and demethylases [24]. Our microarray data suggested 
the reciprocal up-regulation of methyltransferases and 
down-regulation of demethylases specific for H3K9me3 
(Supplementary Table 2). Probing for SETDB1, SETDB2, 
EHMT2, SUV39H1, PRDM3, and KDM4B using qRT-
PCR in WM164, WM1366, A549, and HT29 showed 
a consistent upregulation of SETDB1, SETDB2 and 
inconsistent changes in the expression of other histone 
modifiers in all IDTCs compared to their parental cells 
(Figure 5a). Higher expression of SETDB1, SETDB2 
and H3K9me3 was confirmed at the protein level in four 
IDTC models representative of melanoma, lung and colon 
cancer (Figure 5b). Additionally, chronic exposure to 
dabrafenib and docetaxel at high concentrations led to a 
similar transition to the IDTC state involving SETDB1, 
SETDB2 and H3K9me3 up-regulation (Figure 5c). 
However, short exposure to dabrafenib, docetaxel, and 
doxorubicin for 72 hours did not induce SETDB1/2 and 
H3K9me3 which proposes that these changes are indeed 
features of the IDTC state (Supplementary Figure 8a). 
These observations suggest that increased expression 
of histone methyltransferases SETDB1 and SETDB2 
stabilize H3K9me3 which is characteristic across different 
cancer types as a generic response towards stress. This 
in vitro increase of H3K9me3 was further confirmed in 
a melanoma xenograft model. Tumours generated by 
injecting 1x106 WM164 melanoma cells and treated with 
dabrafenib (10mg/Kg) and trametinib (0.1mg/Kg) after 
formation of tumours (200mm3) for 21 days, resembling 
the in vitro observations, showed an increase of H3K9me3 
compared to control (Figure 5d, Supplementary Figure 
8b). For further validation paired clinical specimens from 
melanoma patients treated with targeted therapies were 
analysed (Supplementary Table 3). RNA-seq data showed 
a significant up-regulation of SETDB2 after therapy and 
a decrease in EZH2, a methyltransferase of H3K27me3, 
with a trend towards increased SETDB1. KDM5B was 
either up- or downregulated (Figure 5e).
Silencing of SETDB1 and SETDB2 restores drug 
sensitivity
Knockdowns of SETDB1 or SETDB2 lead 
to a significant reduction of H3K9me3 (Figure 5f). 
Interestingly, knockdown inhibited the acquisition of 
induced drug tolerance. This was evidenced by loss 
of H3K9me3 but gain of H3K4me3 and H3K27me3 
compared to shcontrol cells indicating a switch of the 
characteristic expression of histone marks found in 
IDTCs. shSETDB1 cells exposed to dabrafenib gained a 
preferential growth advantage by forming cellular clusters 
(Figure 5g). shcontrol IDTC, shSETDB1 and shSETDB2 
cells were further exposed to high concentrations of 
docetaxel (30nM) or doxorubicin (2.5µM) which renders 
the sensitivity of shSETDB1/2 treated cells (P < 0.0001) 
but not shcontrol IDTC (Figure 5f). A similar effect 
was observed in shSETDB1/2 A549 cells compared to 
shcontrol (Supplementary Figure 8c-8e).
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Figure 4: Genome-wide re-distribution of histone modifications in IDTCs. a. Genome-wide levels of histone modifications are 
represented by the mean number of segments with ChIP-seq peaks 20kb around 100,000 randomly selected genome segments (upper panel). 
The association with transcriptomic changes is represented as the distribution of each histone modification around the transcription start 
sites (TSSs) of 1,423 genes down-regulated (fold change <-2) in IDTC cells (lower panels). b. Re-distribution of histone modifications in 
IDTCs was evaluated on 1,245 polycomb repressive domains (PRDs) associated with IDTC down-regulated genes. c. A significant overlap 
was observed between down-regulated genes (n = 1,423) and genes associated with H3K9me3 (n = 4,969)(n = 487; exact hypergeometric 
probability; P = 5.38x 10-22) as well as for regions between up-regulated genes (fold change >2; n = 1,087) and genes associated with 
H3K4me3 (n = 1,487)(n = 138; exact hypergeometric probability; P = 3.15x10-12) and between downregulated genes (n = 1423) and 
genes associated with H3K27me3 (n = 370; exact hypergeometric probability P = 0.03). d. Representative genomic view of the inversely 
correlated H3K4me3 and H3K9me3 modifications in IDTCs. The chromatin states were identified by calculating the Epilogos score 
(https://epilogos.altiusinstitute.org/) from the integration of the Core 15-state model using 111 reference human epigenomes generated by 
the Roadmap Epigenomics Project [23] plus 16 human epigenomes generated by the ENCODE Project. Two PRDs showing enrichment in 
H3K9me3 and depletion of H3K4me3 leading to a regional (2.6 Mb window) transcriptional down-regulation in IDTCs.
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Figure 5: SETDB1 and SETDB2 regulate H3K9me3 in IDTCs and knockdown restores drug sensitivity. a. RNA was 
isolated from different IDTCs and their parental cells.  q-RTPCR was performed for the different histone modifiers of H3K9me3. Actin 
RNA was used as an internal control and relative gene expression levels were calculated as delta CT. Bars represent the mean of three 
biological replicates. Statistical analysis was performed by two-way ANOVA test and P-value is represented as (*) where, ****P < 0.0001, 
***P < 0.001, **P < 0.01, and *P < 0.05. b. Proteins were isolated from different IDTCs and their respective parental cells. Immunoblots 
were performed to investigate the expression of SETDB1, SETDB2, and H3K9me3. c. WM164, WM1366, and HT29 cells were exposed 
to 100nM dabrafenib, 10nM docetaxel and 100nM dabrafenib respectively for two weeks. Proteins were isolated from IDTCs and untreated 
control and immunoblotted for SETDB1, SETDB2 and H3K9me3. All western blot images were quantified by ImageJ software. Values 
were normalized by subtracting from loading control. d. Tumour tissue was formalin fixed and tissue slides were stained for H3K9me3. 
Images were taken in a Vectra III Spectral scanner. e. RNA-sequencing data of paired pre- and post-treatment tumour biopsies derived from 
melanoma patients from GEO [55] were normalized, background-corrected and analysed using the R package “lumi”. Statistical analyses 
were performed by paired t-test where, **P < 0.01, *P < 0.05. Each paired match-patient expression value for an individual gene is shown 
by different colours. Numeric values indicate the patient number as provided in Supplementary Table 2. BT- Before treatment, AT- After 
treatment. f. Lentiviral transduction was performed according to manufacturer protocol (Sigma Aldrich, MA, USA). Protein lysates of 
the transduced cells were subjected to immunoblotting for SETDB1, SETDB2, H3K9me3 and Actin. g. WM164 shcontrol, shSETDB1, 
and shSETDB2 transduced cells were exposed for 16 days to 50nM dabrafenib and stained for H3K4me3, H3K9me3, and H3K27me3 by 
immunofluorescence. h. Same as in (g) but in addition challenged with toxic concentrations of docetaxel (30nM) and doxorubicin (2.5µM). 
Cell survival was analysed by MTT assay. Statistical analysis was performed by two-way ANOVA test and P-value is represented as (*) 
where, ****P < 0.0001. All western blot images were quantified by ImageJ software. Values were normalized by subtracting from loading 
control.
Oncotarget8215www.impactjournals.com/oncotarget
DISCUSSION
Cancer cells exert an innate response towards 
different stressors transforming them into a stress-
resistant slow proliferative state by histone remodelling. 
These induced drug-tolerant cells (IDTCs) exhibit 
cross-resistance to much higher concentrations of the 
same or other drugs [12]. IDTCs are characterised by 
the upregulation of CD271, multidrug resistance and 
increased expression of major signalling pathways 
such as the MAPK (Raf/Ras/MEK/ERK) and the PI3K/
AKT/mTOR. Histone remodelling is characteristic of 
IDTCs along with alterations of signalling cascades 
during this transformation. We have found that the 
transcriptional active mark H3K4me3 and the repressive 
mark H3K27me3 decreased, whereas a repressive mark 
H3K9me3 increased at the IDTC state compared to 
parental cells (Figure 6a). This is in line with the previous 
finding of an increase of KDM5B regulating H3K4me3 
and loss of H3K27me3 which was associated with poor 
prognosis and drug resistance in different cancer types [25-
27]. Previous studies indicated that H3K9me3 correlates 
with tumour suppressor gene silencing and the increase 
of H3K9me3 being a strong predictor of poor survival in 
different cancer types [28-30]. We found that accumulation 
of the repressive mark H3K9me3 along with loss of the 
active mark H3K4me3 is associated with the ability 
of cancer cells to survive early stress. The continued 
survival of these cells in the presence of drug allows these 
cells to establish over time irreversible drug resistance 
mechanisms. Employing a timely drug holiday causes 
epigenetic reprogramming to a similar histone methylation 
Figure 6: Model (a) Stress induce cancer cells to undergo a dynamic histone reprogramming with the increase of repressive 
histone mark H3K9me3 and decrease of active mark H3K4me3 and repressive mark H3K27me3. These distinct histone 
modifications help cancer cells to maintain a transcriptionally repressed slow cycling state. Drug holiday reversed the histone modifications 
similar to that of parental cells which induce sensitivity. b. Upon drug treatment silenced SETDB1/2 cancer cells reprogram their histone 
modifications which are sensitive to other drugs.
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pattern as parental cells. Cancer cells suffer a fitness 
deficit upon drug withdrawal which renders them again 
sensitive to the drug (Figure 6a), a phenomenon recently 
described [11]. A previous study denotes that drug holiday-
induced sensitivity towards the same therapy is due to 
an oncogene-induced senescence-like state by supra-
physiological levels of BRAF-MEK-ERK1/2 signalling in 
melanoma [31]. Along this line it was reported that ERK2 
binding to promoter regions induces the H3K4me3 mark 
in human embryonic stem cells [32]. However, the detailed 
underlying mechanism of regulating histone modifications 
upon drug holiday requires further investigation. This 
suggests that cancer cells exhibit a generic response to 
stress at the initial stage but can reverse their epigenetic 
makeup depending on the context demonstrating 
phenotypic plasticity in cancer [33]. Our study shows 
that IDTCs have a reduced global gene expression level 
compared to their respective parental cells and suggests 
that the IFN-α, -β, -γ signalling and cytokine signalling 
pathways are crucial for all IDTCs. This is supported by 
recent findings of constitutive activation of STAT/IFN 
signalling linked to drug resistance in different cancers 
[34, 35]. Other studies report that methyltransferases of 
H3K9 such as SETDB1 and SUV39H1 interact with DNA 
methyltransferases DNMT3B and DNMT3A, respectively, 
providing a functional link between DNA methylation 
and H3K9me3 modification [22, 36]. We found that there 
were no significant changes of global CpG methylation 
common to all IDTCs, suggesting that DNA methylation 
changes follow a cancer type-specific program. Our data 
demonstrate that IDTCs from different cancer types exhibit 
a specific DNA methylation reprogramming that might not 
be generalized as a mechanism for the acquisition of drug 
tolerance. This is in line with an earlier study where it has 
been reported that deletion of DNMTs has no effect on 
H3K9me3 marking of pericentromeric heterochromatin in 
mice suggesting that DNA methylation at genic promoters 
is only weakly correlated with H3K9me2 or H3K9me3 in 
somatic cells and mouse embryonic stem cells [37, 38]. 
In parallel, another study demonstrated that SETDB1/
H3K9me3 and DNMTs mark and regulate a distinct set 
of genes and retroelements in mESC [39]. Altogether, 
these findings suggest that histone modifications can act 
independently of DNA methyltransferases (DNMTs) 
repressing a target set of genes.
Whole-genome redistributions of H3K4me3 and 
H3K9me3 suggest that due to the global decrease of the 
active histone mark H3K4me3 and the regional increase 
of H3K9me3 a subset of genes are transcriptionally 
suppressed in IDTCs. This is in line with previous 
findings claiming that genomic regions with loss of the 
active histone mark H3K4me3 but gain of the repressive 
mark H3K9me3 are associated with down-regulation of 
genes [40]. Here we show to the best of our knowledge 
for the first time dynamics in histone modifications 
which are associated with transcriptional repression 
at early drug resistance in cancer. ChIP-microarray 
overlay also suggests that polycomb repressor domains 
are downregulated due to the increase in H3K9me3 and 
decrease of H3K4me3 mark which supports previous 
findings on the association of drug resistance in cancer 
with the concomitant loss of the components of polycomb 
repressor complex [41, 42]. This implies that the interplay 
amongst active and repressive histone modifications are 
decisive to regulate gene expression in response to drugs 
or other stressors in cancer cells. 
Previously it has been shown that stable knockout 
of KDM5B reversed the slow cycling population in 
melanoma cells [43]. In our previous study, stable 
knockdown of KDM5B restored drug sensitivity 
the reminiscent population, however, exhibited drug 
resistance against single or combinatorial treatments 
resembling IDTCs [12]. However, stable knockdown of 
SETDB1/2 in this study reversed early acquired drug 
resistance with dynamic re-enhancement of the active 
mark H3K4me3 (Figure 6b). The underlying mechanisms 
of histone modifications are poorly understood although 
some studies demonstrated the role of signalling cascades 
in regulating histone modifiers in a context-dependent 
manner. Insulin growth factor 1 receptor (IGF1R) was 
found to be a direct regulator of KDM5A in a drug-
tolerant model. Inhibition of IGF1R ablated the drug-
resistant state by downregulating KDM5A resulting in 
an increase of the H3K4me3 mark [6]. Another study 
revealed that activated AKT phosphorylates EZH2 and 
BM1 resulting in inhibition of H3K27 methylation by 
suppressing the methyl transferase activity of EZH2 [44]. 
Further type1 interferon (IFN1) signalling was reported 
to induce SETDB2 mediated H3K9me3 marking on 
several antiviral effector genes resulting in transcriptional 
repression upon influenza A virus infection in a murine 
and human macrophage model [45]. Indeed, we have 
observed a consistent activation of PI3K/AKT and 
IFN1/STAT1 signalling which might play a role in the 
concomitant modulation of the histone marks. Along 
this line, our previous study revealed that combined 
inhibition by using PI3K/AKT, IGF1R inhibitors along 
with the primary drug eliminates the IDTC transition from 
parental cells, however, IDTCs displayed tolerance once 
they are exposed to combined inhibitors [12]. Therefore, 
we propose that stress-induced multiple signalling 
cascades might play a crucial role in the acquisition and 
regulation of distinct histone modifications leading to 
global transcriptional downregulation. Our findings reveal 
generic changes of histone modifications in cancer upon 
drug exposure and nutrient starvation. This also implies 
that a defined epigenetic modification is pivotal in IDTCs 
to maintain a slow proliferative state in response to stress 
and targeting histone modifiers might prevent the IDTC 
transition from parental cells.
This study focused on the early time point of 
acquired drug resistance in cancer, therefore SETDB1/2 
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mediated increment of H3K9me3 mark along with 
concomitant loss of H3K4me3 is limited to the early 
phase of stress tolerance in cancer. It will be important 
to investigate the role of distinct histone remodelling 
in acquired drug resistance with a prolonged time point 
which might simulate the relapse of cancer patients.
In the future, it will be crucial to underpin the 
role of upstream signalling cascades such as IFN and 
cytokine signalling involved in the distinct modification 
of histone marks from parental to IDTCs. A more 
detailed understanding of early drug tolerance will allow 
identification of potential targets as epigenetic ‘drivers’ of 
this process which implemented in addition to established 
treatments might prevent the transition to permanent 
resistance. 
MATERIALS AND METHODS
Antibodies and reagents
CD271, SETDB1, SETDB2, p-mTOR and Actin 
antibodies were purchased from Abcam, (CBG, UK). 
Phosphorylated AKT-Ser473 (pAKT), total AKT (T-AKT), 
phosphorylated ERK1,2-Thr202/Tyr204 (p-ERK1,2), 
total ERK (ERK1,2) antibodies were obtained from 
Cell Signalling Technology, (MA, USA). Antibodies for 
H3K4me3, H3K9me3 and H3K27me3 were purchased 
from Active Motif (CA, USA). Alexa Fluor 594 antibody 
and Hoechst 33342 were obtained from Thermo Fisher 
Scientific (MA, USA).
Drugs
Chemotherapeutic drugs doxorubicin, docetaxel, 
and cisplatin and targeted inhibitors such as dabrafenib, 
trametinib, erlotinib were purchased from Selleck 
Biochem, TX, USA.
Cell lines
Melanoma cell lines WM164, WM1366 were 
obtained from The Wistar Institute. Lung cancer cell line 
A549, colon cancer cell line HT29 and hepatocellular 
carcinoma cell line HEPG2 were kindly provided by Dr 
Gerald Hoefler from the Medical University of Graz, 
Austria. HCC827 cell line was kindly provided by Dr 
Derek Richard, The University of Queensland, Brisbane, 
QLD. The SKBR3 cell line was kindly provided by Dr 
Fiona Simpson, UQDI, The University of Queensland, 
Brisbane, QLD. Cell lines are authenticated by STR 
profiling and tested for mycoplasma contamination
Cell culture
Cells were cultured in RPMI media (Life technology, 
USA) supplemented with 5% heat-inactivated fetal bovine 
serum (FBS, Sigma, MI), 10% of L-Glutamine and 10% 
of penicillin-streptomycin antibiotics (Life Technologies, 
CA).
Drug treatment and nutrient starvation
Cancer cells were exposed to either DMSO or 
sub-lethal dosages of different drugs such as dabrafenib, 
docetaxel, doxorubicin and erlotinib for 12-15 days for the 
generation of IDTCs. For nutrient starvation cancer cells 
were cultured with 1mg/ml glucose containing media for 
at least 12 days. Media and drugs were replenished every 
three days.
Drug holiday
Cancer cells were continuously exposed to various 
stresses (different drugs, nutrient starvation) for 12-15 
days for generating IDTCs. After formation of IDTCs, the 
drug was withdrawn and cells kept in culture for another 
10 days as suggested based on clinical trials [46]. Media 
was replenished every three days. 
Crystal violet staining
IDTCs and their parental cells were washed with 
1XPBS and then fixed with 4% paraformaldehyde, 
followed by 30 min incubation. Fixed cells were incubated 
with 0.05% crystal violet solution in 1xPBS for one hour. 
The plates were then washed three times with reverse 
osmosis (RO) H2O and pictures were taken using the Bio 
Rad gel documentation unit after drying.
Cell survival assay
Cell survival was analysed by MTT assay. Briefly, 
2x104 cells were seeded in 96-well culture plates. On the 
following day cells were exposed to the drugs as indicated 
above and after 72 hrs of drug exposure cells were 
incubated with MTT (3-(4, 5-dimethylthiazolyl-2)-2,5 
diphenyltetrazolium bromide) reagent (Life Technologies, 
CA) (10µl) at 37ºC for 4hrs. 100µl detergent reagent was 
then added to the wells and incubated in the dark at room 
temperature for 4hrs. Absorbance was measured at 570nm 
using a microtiter plate reader.
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Cell lysates and immunoblots
Immunoblotting was performed as previously 
described [47]. Briefly, cell pellets were lysed with RIPA 
buffer for protein isolation. Protein samples were treated 
with protease and phosphatase inhibitor cocktail before 
immunoblotting. Protein concentrations were determined 
by BCA standard solution. Equal amounts of protein 
were loaded onto 10% SDS-PAGE gels. Polyvinylidene 
difluoride (PVDF) membrane was used for wet transfer. 
Transferred proteins were blocked with either 5% BSA 
(for phosphorylated proteins) or 5% milk in 1xTBST for 
one hour at room temperature. The membrane was then 
incubated with a specific primary antibody overnight at 
4oC, then washed three times with 1xTBST and incubated 
with a secondary antibody at room temperature for 1hr 
followed by three washes with 1xTBST. The membrane 
was developed with ECL solution and image taken with 
LI-COR C-DiGiT western blot scanner.
Immunofluorescence
Immunofluorescence(IF) analysis was performed 
as described previously [12]. Briefly, treated or untreated 
cells were fixed with 4% paraformaldehyde in PBS for 
30minutes and then blocked with 0.3% Triton X-100, 5% 
goat serum and 1% BSA dissolved in PBS. Cells were 
incubated with the primary antibody at 4oC overnight; 
followed by three washes with 1% BSA in PBS on the 
following day. Cells were incubated with Alexa fluoro 594 
secondary antibody for one hour along with Hoechst dye 
for the nuclear staining. All images were taken with an 
Olympus inverted fluorescent microscope.
RNA isolation and q-RTPCR
Total RNA was isolated and cDNA was synthesized 
according to the manufacturer’s protocol (Bioline, MA, 
USA cat. BIO-65043). The SensiFast SYBR Lo-ROX 
master mix from Bioline was used to amplify the specific 
genes and products were detected by the VIIA-7 machine 
of Applied Biosystem. The following primers were used: 
SETDB1 for 5’- GCTGAGACACCAAACGTCAAAA-3’, 
rev 5’-ACATAGGAAGCATAGCCATCATCA-3’, 
SETDB2 for 5’-GAGTCTGCAGAACGGCATC-3’,rev 
5’-CACGCCCACATCACTGTAGA-3’, SUV39H1 
for 5’-GTCATGGAGTACGTGGGAGAG-3’, 
rev 5’-CCTGACGGTCGTAGATCTGG-3’, G9a 
for 5’-TGGGAAAGGTGACCTCAGAT-3’ , rev 
5’-TCCCTGACTCC TCATCTTCC-3’, PRDM3 for 
5’-GAAAATGGTAAAATGTTCAAAGACA-3’, rev 
5’-CACCAGTCCTGTTGAACCAA-3’, KDM4B 
for 5’-GACATCAGCGGCTCTTTGTATGATG-
3’,rev 5’-ATGCCGAAGTACAGGTAGGGCGTG-3’, 
Actin for 5’-CCACACTGTGCCCATCTACG-3’, rev 
5’-AGGATCTTCATGAGGTAGTCAGTCAG-3’.
Lentiviral transduction
Lentiviral transduction was performed according 
to manufacturer protocol (Sigma Aldrich, MA, USA). 
Briefly, WM164 cells were seeded and on the following 
day media were changed to polybrene (8ug/ml) containing 
media and incubated with lentiviral particles which were 
further selected for 2 weeks with 5µg/ml puromycin. Cells 
were transduced with lentiviral particles of non-target 
shRNA control (SHC016V, Sigma, MA), SETDB1 target 
shRNA (SHCLNV-NM_012432) and SETDB2 target 
shRNA (SHCLNV-NM_031915).
In-vivo tumour staining
The frozen sections of harvested tumours were 
embedded in OCT (PST-IA018), QLD, Australia cut 
and transferred onto slides. The slides were fixed for 10 
minutes in 4% paraformaldehyde and washed twice in 
PBS for 5 minutes each. The cells were permeabilized 
for 30 minutes in 0.2% Triton X and washed twice with 
PBS for 5 minutes each. 5% goat serum/1% BSA/0.2% 
Triton X 100 solution was used to block the slides for 
one hour. Slides were then incubated overnight at 4oc 
with the primary antibody diluted in blocking solution. 
Further, they were washed twice for 30 minutes in PBS. 
Slides were then incubated at room temperature with the 
respective secondary antibody in blocking solution for 2 
hours, followed by 20 minutes in Hoechst nuclear stain 
and visualised under an Olympus IX73 microscope. The 
images were analysed by image J. All animal experiments 
were performed in accordance with institutional guidelines 
Ethics number: SOM/TRI/197/15/DRC.
Microarray
Four cancer cell lines were analysed for genome-
wide differential expression by Illumina expression 
array by the Australian Genome Research Facility 
(AGRF). These are WM1366 IDTCs (melanoma), A549 
IDTCs (lung cancer), HT29 IDTCs (colon cancer), 
HCC827 IDTCs (EGFR mutant lung cancer) and their 
corresponding parental controls. The data was read 
into R using the Bioconductor package limma, 5, 6 
and underwent normalization expression background 
correction using negative controls, quantile normalisation 
and then log2 transformed. The control probes were 
removed. All probes not expressed in the samples of 
interest were removed, resulting in 23,422 probes and 24 
samples. A linear model was fitted contrasting the controls, 
resulting in all differentially expressed genes under a false 
Oncotarget8219www.impactjournals.com/oncotarget
discovery rate of 5%. The relative reliability of each array 
was estimated by measuring how well the expression 
values for that array follow the linear model.
Genome-wide DNA methylation
Genome-wide DNA methylation assays were 
performed using the HM450K BeadChip (Illumina, Inc., 
Carlsbad, CA) platform as previously described [48]. The 
chips were scanned with Illumina iScan (Illumina, Inc.), 
and data was extracted using the R package methylumi. 
The ‘noob’ function in the R package minfi was used to 
process the data and then the ‘dasen’ function in the R 
package water melon for normalisation and dye-bias 
correction. DNA methylation levels were reported as 
β-value (β = intensity of the Methylated allele/(intensity 
of the Unmethylated allele + intensity of the Methylated 
allele)) and calculated using the signal intensity value for 
each CpG site.
Chromatin immunoprecipitation (ChIP)
ChIP of WM164 IDTCs and parental cells were 
performed according to the manufacturer instructions 
(Active Motif, CHIP-IT Express Enzymatic Kit, Catalogue 
Numbers, 53009, 53035). Briefly, WM164 IDTCs and 
parental cells were formalin fixed for chromatin isolation. 
Isolated nuclei pellets were sonicated three times for 30s 
and then treated with an enzymatic shearing cocktail. 12 
microgram of sheared chromatin was used for all samples 
for immunoprecipitation with the specific antibodies. 
ChIPed DNA concentration was measured in Qubit with 
high sensitivity dsDNA kit.
ChIP-Sequencing
Chromatin immunoprecipitation sequencing (ChIP-
Seq) was performed for H3K27me3, H3K4me3, and 
H3K9me3 on biological duplicates for paired parental and 
IDTC cells. ChIP-seq peaks were called as we previously 
described [49]. Briefly, raw sequence reads were mapped 
to the 1000 Genomes (b37) build of the human genome 
reference using BWA (version 0.7.5a) with default settings 
[50] and duplicates were marker using Picard Tools 
(version 1.103) (http://broadinstitute.github.io/picard/). 
Peaks were identified using the call peaks function 
in MACS2 [51] with a threshold set to -q = 0.01 and 
BigWig files were generated using bedGraphToBigWig 
[52]. BigWig files processing was performed using the 
deepTools webserver [53].
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